http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36522388

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, Non-U.S. Gov't
issn 2051-1426
issueIdentifier 9
pageRange e007099-
publicationName Journal for ImmunoTherapy of Cancer
startingPage e007099
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_bfd0e6912e1a0ebf2534c831dfb49332
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d74d8b58080c8e4d52ac61a54e829bfe
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_cabe87d97f122d4519c6b14d45d1248c
bibliographicCitation Wang Y, He M, Zhang C, Cao K, Zhang G, Yang M, Huang Y, Jiang W, Liu H. Siglec-9+tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer. J Immunother Cancer. 2023 Sep;11(9):e007099. doi: 10.1136/jitc-2023-007099.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0200-8981
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2df5d7abe043b62a080957d60e01beaf
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741734cd7dc29bb1028a5f74caeee1c9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69330bddc880973b1409249c6911b122
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab3575a242c925278ae80d2ad1c7eea3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ebc4a9a70184f8bbc0a194bd6be8470e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_999e273b0abaafa6f47b3bb28358f572
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_487bf7606ab54e2dbae9e169c07901ef
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43e4bf693e07e9a53a19633168b628ac
date 202309
identifier https://pubmed.ncbi.nlm.nih.gov/PMC10503378
https://pubmed.ncbi.nlm.nih.gov/37709296
https://doi.org/10.1136/jitc-2023-007099
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/41915
https://portal.issn.org/resource/ISSN/2051-1426
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Siglec-9+tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
discusses http://id.nlm.nih.gov/mesh/M0001352
http://id.nlm.nih.gov/mesh/M0011171
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D010051Q000188
http://id.nlm.nih.gov/mesh/D000084582
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D059016
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D000906
http://id.nlm.nih.gov/mesh/D007167
http://id.nlm.nih.gov/mesh/D007166

Total number of triples: 40.